In a randomized trial, the live attenuated tetravalent dengue vaccine TV003 is well-tolerated and highly immunogenic in subjects with flavivirus exposure prior to vaccination.
Infection caused by the four serotypes of dengue virus (DENV-1-4) is a leading cause of mosquito-borne disease. Clinically-severe dengue disease is more common when secondary dengue infection occurs following prior infection with a heterologous dengue serotype. Other flaviviruses such as yellow feve...
Published in: | PLOS Neglected Tropical Diseases |
---|---|
Main Authors: | , , , , , , , , , , , , , , , , , |
Format: | Article in Journal/Newspaper |
Language: | English |
Published: |
Public Library of Science (PLoS)
2017
|
Subjects: | |
Online Access: | https://doi.org/10.1371/journal.pntd.0005584 https://doaj.org/article/e82e1eafdd91482ea97da5ea467acf14 |
id |
ftdoajarticles:oai:doaj.org/article:e82e1eafdd91482ea97da5ea467acf14 |
---|---|
record_format |
openpolar |
spelling |
ftdoajarticles:oai:doaj.org/article:e82e1eafdd91482ea97da5ea467acf14 2023-05-15T15:18:11+02:00 In a randomized trial, the live attenuated tetravalent dengue vaccine TV003 is well-tolerated and highly immunogenic in subjects with flavivirus exposure prior to vaccination. Stephen S Whitehead Anna P Durbin Kristen K Pierce Dan Elwood Benjamin D McElvany Ellen A Fraser Marya P Carmolli Cecilia M Tibery Noreen A Hynes Matthew Jo Janece M Lovchik Catherine J Larsson Elena A Doty Dorothy M Dickson Catherine J Luke Kanta Subbarao Sean A Diehl Beth D Kirkpatrick 2017-05-01T00:00:00Z https://doi.org/10.1371/journal.pntd.0005584 https://doaj.org/article/e82e1eafdd91482ea97da5ea467acf14 EN eng Public Library of Science (PLoS) http://europepmc.org/articles/PMC5436874?pdf=render https://doaj.org/toc/1935-2727 https://doaj.org/toc/1935-2735 1935-2727 1935-2735 doi:10.1371/journal.pntd.0005584 https://doaj.org/article/e82e1eafdd91482ea97da5ea467acf14 PLoS Neglected Tropical Diseases, Vol 11, Iss 5, p e0005584 (2017) Arctic medicine. Tropical medicine RC955-962 Public aspects of medicine RA1-1270 article 2017 ftdoajarticles https://doi.org/10.1371/journal.pntd.0005584 2022-12-31T02:10:49Z Infection caused by the four serotypes of dengue virus (DENV-1-4) is a leading cause of mosquito-borne disease. Clinically-severe dengue disease is more common when secondary dengue infection occurs following prior infection with a heterologous dengue serotype. Other flaviviruses such as yellow fever virus, Japanese encephalitis virus, and Zika virus, can also elicit antibodies which are cross-reactive to DENV. As candidate dengue vaccines become available in endemic settings and for individuals who have received other flavivirus vaccines, it is important to examine vaccine safety and immunogenicity in these flavivirus-experienced populations. We performed a randomized, controlled trial of the National Institutes of Health live attenuated tetravalent dengue vaccine candidate (TV003) in fifty-eight individuals with prior exposure to flavivirus infection or vaccine. As in prior studies of this vaccine in flavivirus-naive volunteers, flavivirus-experienced subjects received two doses of vaccine six months apart and were followed closely for clinical events, laboratory changes, viremia, and neutralizing antibody titers. TV003 was well tolerated with few adverse events other than rash, which was predominately mild. Following one dose, 87% of vaccinees had an antibody response to all four serotypes (tetravalent response), suggesting a robust immune response. In addition, 76% of vaccinees were viremic; mean peak titers ranged from 0.68–1.1 log10 PFU/mL and did not differ by serotype. The second dose of TV003 was not associated with viremia, rash, or a sustained boost in antibody titers indicating that a single dose of the vaccine is likely sufficient to prevent viral replication and thus protect against disease. In comparison to the viremia and neutralizing antibody response elicited by TV003 in flavivirus-naïve subjects from prior studies, we found that subjects who were flavivirus-exposed prior to vaccination exhibited slightly higher DENV-3 viremia, higher neutralizing antibody titers to DENV-2, -3, and -4, and a ... Article in Journal/Newspaper Arctic Directory of Open Access Journals: DOAJ Articles Arctic PLOS Neglected Tropical Diseases 11 5 e0005584 |
institution |
Open Polar |
collection |
Directory of Open Access Journals: DOAJ Articles |
op_collection_id |
ftdoajarticles |
language |
English |
topic |
Arctic medicine. Tropical medicine RC955-962 Public aspects of medicine RA1-1270 |
spellingShingle |
Arctic medicine. Tropical medicine RC955-962 Public aspects of medicine RA1-1270 Stephen S Whitehead Anna P Durbin Kristen K Pierce Dan Elwood Benjamin D McElvany Ellen A Fraser Marya P Carmolli Cecilia M Tibery Noreen A Hynes Matthew Jo Janece M Lovchik Catherine J Larsson Elena A Doty Dorothy M Dickson Catherine J Luke Kanta Subbarao Sean A Diehl Beth D Kirkpatrick In a randomized trial, the live attenuated tetravalent dengue vaccine TV003 is well-tolerated and highly immunogenic in subjects with flavivirus exposure prior to vaccination. |
topic_facet |
Arctic medicine. Tropical medicine RC955-962 Public aspects of medicine RA1-1270 |
description |
Infection caused by the four serotypes of dengue virus (DENV-1-4) is a leading cause of mosquito-borne disease. Clinically-severe dengue disease is more common when secondary dengue infection occurs following prior infection with a heterologous dengue serotype. Other flaviviruses such as yellow fever virus, Japanese encephalitis virus, and Zika virus, can also elicit antibodies which are cross-reactive to DENV. As candidate dengue vaccines become available in endemic settings and for individuals who have received other flavivirus vaccines, it is important to examine vaccine safety and immunogenicity in these flavivirus-experienced populations. We performed a randomized, controlled trial of the National Institutes of Health live attenuated tetravalent dengue vaccine candidate (TV003) in fifty-eight individuals with prior exposure to flavivirus infection or vaccine. As in prior studies of this vaccine in flavivirus-naive volunteers, flavivirus-experienced subjects received two doses of vaccine six months apart and were followed closely for clinical events, laboratory changes, viremia, and neutralizing antibody titers. TV003 was well tolerated with few adverse events other than rash, which was predominately mild. Following one dose, 87% of vaccinees had an antibody response to all four serotypes (tetravalent response), suggesting a robust immune response. In addition, 76% of vaccinees were viremic; mean peak titers ranged from 0.68–1.1 log10 PFU/mL and did not differ by serotype. The second dose of TV003 was not associated with viremia, rash, or a sustained boost in antibody titers indicating that a single dose of the vaccine is likely sufficient to prevent viral replication and thus protect against disease. In comparison to the viremia and neutralizing antibody response elicited by TV003 in flavivirus-naïve subjects from prior studies, we found that subjects who were flavivirus-exposed prior to vaccination exhibited slightly higher DENV-3 viremia, higher neutralizing antibody titers to DENV-2, -3, and -4, and a ... |
format |
Article in Journal/Newspaper |
author |
Stephen S Whitehead Anna P Durbin Kristen K Pierce Dan Elwood Benjamin D McElvany Ellen A Fraser Marya P Carmolli Cecilia M Tibery Noreen A Hynes Matthew Jo Janece M Lovchik Catherine J Larsson Elena A Doty Dorothy M Dickson Catherine J Luke Kanta Subbarao Sean A Diehl Beth D Kirkpatrick |
author_facet |
Stephen S Whitehead Anna P Durbin Kristen K Pierce Dan Elwood Benjamin D McElvany Ellen A Fraser Marya P Carmolli Cecilia M Tibery Noreen A Hynes Matthew Jo Janece M Lovchik Catherine J Larsson Elena A Doty Dorothy M Dickson Catherine J Luke Kanta Subbarao Sean A Diehl Beth D Kirkpatrick |
author_sort |
Stephen S Whitehead |
title |
In a randomized trial, the live attenuated tetravalent dengue vaccine TV003 is well-tolerated and highly immunogenic in subjects with flavivirus exposure prior to vaccination. |
title_short |
In a randomized trial, the live attenuated tetravalent dengue vaccine TV003 is well-tolerated and highly immunogenic in subjects with flavivirus exposure prior to vaccination. |
title_full |
In a randomized trial, the live attenuated tetravalent dengue vaccine TV003 is well-tolerated and highly immunogenic in subjects with flavivirus exposure prior to vaccination. |
title_fullStr |
In a randomized trial, the live attenuated tetravalent dengue vaccine TV003 is well-tolerated and highly immunogenic in subjects with flavivirus exposure prior to vaccination. |
title_full_unstemmed |
In a randomized trial, the live attenuated tetravalent dengue vaccine TV003 is well-tolerated and highly immunogenic in subjects with flavivirus exposure prior to vaccination. |
title_sort |
in a randomized trial, the live attenuated tetravalent dengue vaccine tv003 is well-tolerated and highly immunogenic in subjects with flavivirus exposure prior to vaccination. |
publisher |
Public Library of Science (PLoS) |
publishDate |
2017 |
url |
https://doi.org/10.1371/journal.pntd.0005584 https://doaj.org/article/e82e1eafdd91482ea97da5ea467acf14 |
geographic |
Arctic |
geographic_facet |
Arctic |
genre |
Arctic |
genre_facet |
Arctic |
op_source |
PLoS Neglected Tropical Diseases, Vol 11, Iss 5, p e0005584 (2017) |
op_relation |
http://europepmc.org/articles/PMC5436874?pdf=render https://doaj.org/toc/1935-2727 https://doaj.org/toc/1935-2735 1935-2727 1935-2735 doi:10.1371/journal.pntd.0005584 https://doaj.org/article/e82e1eafdd91482ea97da5ea467acf14 |
op_doi |
https://doi.org/10.1371/journal.pntd.0005584 |
container_title |
PLOS Neglected Tropical Diseases |
container_volume |
11 |
container_issue |
5 |
container_start_page |
e0005584 |
_version_ |
1766348406757785600 |